Heron Therapeuti
$ 1.09
-8.40%
24 Feb - close price
- Market Cap 199,865,000 USD
- Current Price $ 1.09
- High / Low $ 1.22 / 1.07
- Stock P/E N/A
- Book Value 0.04
- EPS -0.09
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE -24.09 %
- 52 Week High 2.68
- 52 Week Low 1.00
About
Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California.
Analyst Target Price
$4.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-08 | 2025-05-05 | 2025-03-10 | 2024-11-12 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-14 | 2023-08-14 | 2023-05-11 | 2023-03-23 |
| Reported EPS | -0.1 | -0.02 | 0.0134 | 0.02 | -0.0317 | -0.06 | -0.02 | -0.07 | -0.17 | -0.35 | -0.27 | -0.17 |
| Estimated EPS | -0.01 | -0.01 | -0.01 | -0.025 | -0.03 | -0.04 | -0.09 | -0.16 | -0.29 | -0.23 | -0.2 | -0.28 |
| Surprise | -0.09 | -0.01 | 0.0234 | 0.045 | -0.0017 | -0.02 | 0.07 | 0.09 | 0.12 | -0.12 | -0.07 | 0.11 |
| Surprise Percentage | -900% | -100% | 234% | 180% | -5.6667% | -50% | 77.7778% | 56.25% | 41.3793% | -52.1739% | -35% | 39.2857% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.03 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HRTX
2026-02-24 19:52:35
Heron Therapeutics Inc (HRTX) is projected to report a loss of 2 cents per share, according to an earnings preview. This forecast is based on information from Refinitiv.
2026-02-19 07:57:07
Heron Therapeutics (NASDAQ:HRTX) is expected to report its Q4 2025 earnings before market open on Thursday, February 26th, with analysts forecasting an EPS of ($0.03) and revenue of $39.533 million. The stock currently trades around $1.21, with a market capitalization of $221.9 million, and analysts have a consensus "Hold" rating with a target price of $4.50. Institutional investors and hedge funds hold a significant 80.01% stake, with several firms increasing their positions in recent quarters.
2026-02-17 14:27:33
Heron Therapeutics will host a conference call and live webcast on February 26, 2026, at 8:30 a.m. ET to announce its fourth quarter and full year 2025 financial results and discuss recent business developments. The commercial-stage biotechnology company focuses on developing and commercializing therapeutic innovations for acute care and oncology patients. This announcement includes forward-looking statements regarding future expectations and risks.
2026-02-17 13:58:27
Heron Therapeutics, Inc. announced it will host a conference call and live webcast on Thursday, February 26, 2026, at 8:30 a.m. ET. The purpose of the call is to report its fourth quarter and full year 2025 financial results and discuss recent business highlights. Interested parties can register for the call or access the webcast through the company's investor relations website.
2026-02-17 13:28:13
Heron Therapeutics (Nasdaq: HRTX) will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, via a conference call and live webcast at 8:30 a.m. ET. The company will discuss financial performance and recent business highlights, with a replay available on their investor website for 60 days. This announcement continues Heron's pattern of regular communication regarding its financial results and business updates.
2026-02-17 08:30:00
Heron Therapeutics, Inc. announced that it will host a conference call and live webcast on Thursday, February 26, 2026, at 8:30 a.m. ET. The call will cover the company's fourth quarter and full year 2025 financial results and recent business highlights. Interested parties can register via a link for dial-in details or access the webcast through the Investor Relations section of Heron’s website.
